NCT04030169View on ClinicalTrials.gov

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

December 14, 2023

Study Completion Date

December 15, 2023

Conditions
PTSD
Interventions
DRUG

Midomafetamine HCl

Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session

Trial Locations (6)

1535

Sykehuset Østfold Hf, DPS Norder, Moss

12203

Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin, Berlin

250 67

NUDZ - National Institute of Mental Health, Klecany

2342 AX

Stichting Centrum '45/Arq, Oegstgeest

CF14 4XW

University Hospital of Wales - Research Facility, Cardiff

SE5 8AF

The Institute of Psychiatry, Psychology and Neuroscience, London

All Listed Sponsors
collaborator

Multidisciplinary Association for Psychedelic Studies

OTHER

lead

MAPS Europe B.V.

INDUSTRY

NCT04030169 - Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study | Biotech Hunter | Biotech Hunter